secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2024-07-22T23:59:59+00:00
Accession:  0001104659-24-081307
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 3.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar raises $19.4M via warrant exercise; new warrants could add $73.3M
---------------------------------------------------------------------------

- Gross proceeds of ~$19.4M from exercise of Tranche B warrants at reduced price of $2.52/share.
- New Tranche A, B, C warrants could generate up to $73.3M additional gross proceeds if exercised.
- Tranche A warrants ($2.52 exercise) trigger on FDA assigning PDUFA date for iopofosine I 131.
- Tranche B ($4.00) triggers on FDA approval; Tranche C ($5.50) on quarterly revenue >$10M from iopofosine.
- Company expects to file NDA for iopofosine I 131 in Q4 2024, seeking priority review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924081307/0001104659-24-081307-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924081307/tm2419897d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-081307

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer